

# KNOW EARLIER

# INTERVENE SOONER

# AVOID AKI

The **VIDAS® NEPHROCHECK® [TIMP-2 • IGFBP-7]** is an FDA-cleared test to aid in the risk assessment of acute kidney injury (AKI).<sup>1</sup> When used in conjunction with clinical evaluation, such tests allow physicians to make confident patient management decisions.



## INTENDED USE:

The VIDAS® NEPHROCHECK® assay is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and/or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The VIDAS NEPHROCHECK test is intended to be used in patients 21 years of age or older.


VIDAS NEPHROCHECK is an automated test for use on the VIDAS® 3 instrument.



[www.nephrocheck.com/us](http://www.nephrocheck.com/us)

**Know Earlier. Intervene Sooner. Avoid AKI.**

**VIDAS® NEPHROCHECK®**  
[TIMP-2 • IGFBP-7]



## Identify kidney stress before damage occurs

Biomarkers are produced during kidney stress before significant damage occurs, spreading the alarm to nearby cells via TIMP-2 and IGFBP-7.<sup>3</sup> The VIDAS NEPHROCHECK assay is designed to help clinicians identify patients at risk of developing moderate or severe AKI within just 12 hours of assessment.

